Mon, February 4, 2013
Sun, February 3, 2013
Sat, February 2, 2013
Fri, February 1, 2013
Thu, January 31, 2013
Wed, January 30, 2013
Tue, January 29, 2013
[ Tue, Jan 29th 2013 ] - Market Wire
AtheroNova Launches New Website
Mon, January 28, 2013
Sun, January 27, 2013
Sat, January 26, 2013
Fri, January 25, 2013
Thu, January 24, 2013
Wed, January 23, 2013
Tue, January 22, 2013
Mon, January 21, 2013
Fri, January 18, 2013
Thu, January 17, 2013
Wed, January 16, 2013
Tue, January 15, 2013
Mon, January 14, 2013
Fri, January 11, 2013
Thu, January 10, 2013
Wed, January 9, 2013
Tue, January 8, 2013

Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP


//health-fitness.news-articles.net/content/2013/ .. f-investors-of-map-pharmaceuticals-inc-mapp.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of... -- NEW YORK, Jan. 23, 2013 /PRNewswire/ --

NEW YORK, Jan. 23, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of MAP Pharmaceuticals, Inc. ("MAP Pharmaceuticals" or the "Company") (NASDAQ: [ MAPP ]) (ISIN: US56509R1086) (CUSIP: 56509R108) concerning the proposed acquisition of MAP Pharmaceuticals by Allergan, Inc. in a transaction valued at approximately $985 million in cash.

The investigation concerns whether the MAP Pharmaceuticals directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value.  Under the terms of the agreement, MAP Pharmaceuticals shareholders will be entitled to receive $25.00 per share in cash for each share of MAP Pharmaceuticals common stock.  However, at least one analyst noted that the offered price undervalues MAP Pharmaceuticals' new migraine treatment drug Levadex.

MAP Pharmaceuticals shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at [ rswilloughby@pomlaw.com ] or 212-661-1100 or 888-476-6529, ext. 237.

The firm is also investigating actions on behalf of shareholders for the following companies: Arbitron Inc., Net1 Ueps Technologies, Inc., Hi-Crush Partners LP, Intermec, Inc., SandRidge Energy, Inc., Abiomed, Inc., Universal Technical Institute, and Clearwire Corporation, Ameristar Casinos, Inc. K-Swiss, Inc., Neptune Technologies Bioressources, Inc. Telanetix, Inc.

The Pomerantz Firm, with offices in New York, Chicago and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See [ www.pomerantzlaw.com ].

SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP



RELATED LINKS
[ http://www.pomerantzlaw.com ]

Publication Contributing Sources